Global Botulinum Toxin in Urology Market to reach $1.98B by 2035 with 6.08% CAGR, driven by aging population and advanced treatments

The global Botulinum Toxin in Urology Market is projected to grow from approximately USD 1.16 billion in 2026 to USD 1.98 billion by 2035, at a CAGR of 6.08%. Growth is fueled by increasing prevalence of urological disorders like overactive bladder, especially in aging populations, and rising demand for minimally invasive treatments. Key players include CSL Behring, Grifols, and Takeda, with North America leading the market and Asia-Pacific as the fastest-growing region. Advances in injection techniques and healthcare infrastructure improvements are expected to sustain market expansion.